BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 5, 2026
Home » Newsletters » BioWorld

BioWorld

April 30, 2012

View Archived Issues

EUSA Swings an Ideal Exit with the $700M Acquisition by Jazz

The privately held UK specialty oncology firm EUSA Pharma Ltd. is to be acquired by Jazz Pharmaceuticals Inc. in a $700 million cash deal that is motivated by the early commercial success of EUSA's Erwinaze treatment for pediatric acute lymphoblastic leukemia (ALL), approved by the FDA in November 2011. Read More

Vivus Gains ED Approval; Obesity Still Center Stage

As expected, the FDA green-lighted Vivus Inc.'s erectile dysfunction drug Stendra (avanafil) on Friday, but analysts and investors remain focused on the looming July 17 PDUFA date for obesity drug Qnexa (phentermine/topiramate). Read More

Mitochondria's Bacterial Past Is Problem for Failing Hearts

Mitochondria, the energy-producing centers of cells, very likely got their start more than a billion years ago as bacteria that gradually went from a symbiotic relationship to a full-fledged part of the cells they colonized. Read More

Gilead's HIV Franchise Solid; HCV, Quad to Round out 2012

Gilead Sciences Inc. beat revenue estimates for the first quarter, but missed earnings-per-share consensus by 2 cents, as it reported solid sales for its antiviral franchise, including impressive uptake of recently launched triple-drug, single-tablet HIV drug Complera. Read More

Financings Roundup

• Supernus Pharmaceuticals Inc., of Rockville, Md., lowered the range for its proposed initial public offering (IPO). Read More

Other News To Note

• The International Myeloma Foundation, of North Hollywood, Calif., said a new drug application (NDA) has been submitted for pomalidomide, an immunomodulatory agent for multiple myeloma developed by Summit, N.J.-based Celgene Corp. The NDA is seeking use of the drug in patients who no longer respond to other therapies. Read More

Stock Movers

Read More

AAN Roundup

• Chelsea Therapeutics International Ltd., of Charlotte, N.C., said that in its randomized, double-blind, placebo-controlled trial (Study 301), Northera (droxidopa) showed statistical improvement compared to placebo for neogenic orthostatic hypotension. Read More

Pharma: Other News To Note

• Manhattan Pharmaceuticals Inc., of New York, changed its name to TG Therapeutics Inc. and implemented a one for 56.25 reverse stock split, which takes effect on April 30. Read More

Appointments and Advancements

• Veracyte Inc., of South San Francisco, named Richard Kloos senior medical director. Read More

Clinic Roundup

• Savara Pharmaceuticals, of Austin, Texas, reported top-line data from its Phase Ia study of AeroVanc, an inhaled antibiotic. AeroVanc (vancomycin hydrochloride inhalation powder) is a dry powder form of vancomycin in a capsule-based inhaler to treat respiratory methicillin-resistant Staphylococcus aureus infections in patients with cystic fibrosis (CF). Read More

Bench Press

Two Italian teams, one from the San Raffaele Telethon Institute and one from the University of Modena and Reggio Emilia, have shown that during gene therapy, vectors frequently integrate into the host genome in ways that leads to alternative splicing of the proteins they land in. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2026.
  • Pancreas 3D hologram

    ASCO 2026: A revolution in pancreatic cancer

    BioWorld
    At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 2, 2026
  • Liver over digital lens background

    EASL 2026: Emerging liver disease targets to watch

    BioWorld
    At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
  • Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

    ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

    BioWorld
    Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing